Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Inventory-to-Revenue : 0.60 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Swedish Orphan Biovitrum AB's Average Total Inventories for the quarter that ended in Mar. 2024 was $360 Mil. Swedish Orphan Biovitrum AB's Revenue for the three months ended in Mar. 2024 was $601 Mil. Swedish Orphan Biovitrum AB's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.60.

Swedish Orphan Biovitrum AB's Inventory-to-Revenue for the quarter that ended in Mar. 2024 increased from Dec. 2023 (0.55) to Dec. 2023 (0.60)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Swedish Orphan Biovitrum AB's Days Inventory for the three months ended in Mar. 2024 was 220.79.

Inventory Turnover measures how fast the company turns over its inventory within a year. Swedish Orphan Biovitrum AB's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.41.

Swedish Orphan Biovitrum AB Inventory-to-Revenue Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Inventory-to-Revenue Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

0.11

0.15

0.22

0.19

0.16

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventory-to-Revenue	Get a 7-Day Free Trial															0.67	0.80	0.79	0.55	0.60

Competitive Comparison of Swedish Orphan Biovitrum AB's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Inventory-to-Revenue falls into.

Swedish Orphan Biovitrum AB Inventory-to-Revenue Calculation

Swedish Orphan Biovitrum AB's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (321.064	+	377.671)	/	2 )	/	2156.742
=	349.3675					/	2156.742
=	0.16

Swedish Orphan Biovitrum AB's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

	Inventory-to-Revenue (Q: Mar. 2024 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )	/	Revenue (Q: Mar. 2024 )
=	( (377.671	+	342.32)	/	2 )	/	600.886
=	359.9955					/	600.886
=	0.60

Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Swedish Orphan Biovitrum AB's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	359.9955	/	148.781	*	365 / 4
	=	220.79

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Swedish Orphan Biovitrum AB's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	148.781	/	359.9955
	=	0.41

Swedish Orphan Biovitrum AB Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

BIOVF:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).